eLife (Nov 2018)

Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes

  • Diego Balboa,
  • Jonna Saarimäki-Vire,
  • Daniel Borshagovski,
  • Mantas Survila,
  • Päivi Lindholm,
  • Emilia Galli,
  • Solja Eurola,
  • Jarkko Ustinov,
  • Heli Grym,
  • Hanna Huopio,
  • Juha Partanen,
  • Kirmo Wartiovaara,
  • Timo Otonkoski

DOI
https://doi.org/10.7554/eLife.38519
Journal volume & issue
Vol. 7

Abstract

Read online

Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development.

Keywords